United-Guardian Inc manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients, and a line of healthcare products including pharmaceuticals and medical lubricants. Its pharmaceutical products are distributed through national drug wholesalers to pharmacies, physicians, and hospitals. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. The company's majority of revenue is derived from the sales of Pharmaceuticals in the United States.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$7.78 – $8.22
Volume10,019
Market cap$37M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$37.12M
Price / earnings
11.87×
Price / book
3.32×
Price / sales
2.98×
EV / sales
2.87×
EV / EBITDA
10.68×
Profitability
Earnings per share
$0.68
Return on assets
23.26%
Return on equity
27.97%
Dividend yield
6.81%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.5×
Quick ratio
5.92×
Cash ratio
0.73×
Cash flow
Price / cash flow
12.34×
Price / free cash flow
12.62×
Free cash flow
$2.94M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for UG, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$3.49M
$3.11M
$2.87M
$2.96M
$2.26M
$2.84M
$2.48M
$2.48M
Cost of revenue
$1.62M
$1.56M
$1.45M
$1.63M
$1.31M
$1.34M
$1.12M
$1.2M
Gross profit
$1.88M
$1.55M
$1.42M
$1.33M
$953.07K
$1.5M
$1.36M
$1.28M
Selling, general and administrative
$0
$0
$0
$0
$0
$0
$0
$0
Research and development
$121.83K
$124.4K
$115.02K
$124.28K
$117.1K
$107.87K
$114.39K
$131.07K
Total operating expenses
$766.37K
$791.68K
$781.98K
$610.75K
$738K
$801.92K
$747.13K
$725.2K
Operating income
$1.11M
$754.13K
$642.45K
$721.9K
$215.07K
$695.45K
$610.92K
$556.38K
Interest expense
$72.56K
$0
$0
$0
$75.17K
$0
$0
$0
Income before taxes
$1.17M
$917.61K
$1.03M
$817.98K
$326.48K
$790.6K
$707.96K
$640.81K
Income taxes
$242.66K
$189.03K
$214.24K
$168.4K
$58.03K
$163.78K
$147.06K
$137.09K
Net income
$930.91K
$728.58K
$818.9K
$649.58K
$268.44K
$626.83K
$560.9K
$503.72K
Net income attributable to common shareholders
$930.91K
$728.58K
$818.9K
$649.58K
$268.44K
$626.83K
$560.9K
$503.72K
EBITDA
$1.14M
$783.49K
$671.46K
$752.62K
$242.37K
$720.61K
$635.95K
$582.71K
Basic earnings per share
$0.20
$0.16
$0.18
$0.14
$0.06
$0.14
$0.12
$0.11
Diluted earnings per share
$0.20
$0.16
$0.18
$0.14
$0.06
$0.14
$0.12
$0.11
Recent news
Company coverage with links to the original publishers.
United-Guardian, Inc. (UG) reported third-quarter 2026 net sales of $3.49 million, up 54% year-over-year, with net income surging 247% to $930,912. The company achieved broad-based growth across pharmaceuticals, personal care ingredients, and medical lubricants, while expanding gross margins to 53.7% from 42.1%. Stock has risen 28% since earnings announcement, outperforming the S&P 500.
Heather Fisher won an annual stock-picking contest with a 287% average return on three picks, primarily due to an 849% gain in Aehr Test Systems. However, Fisher sold most of her AEHR shares before the dramatic climb, missing out on significant gains. The contest had 42 participants, with 18 beating the S&P 500's 23.3% return.
United-Guardian, Inc. reported Q1 2026 sales increased 15.8% to $2.87M and net income rose 45.9% to $0.18 per share, driven by 24% pharmaceutical sales growth (led by Renacidin) and 21% cosmetic ingredient sales growth. The company also recognized $303K in settlement income from a contract manufacturer. Management expects continued growth in 2026 from normalized distributor purchasing patterns and expanded market outreach.
United-Guardian, Inc. (NASDAQ:UG) reported a 13% decline in net sales to $10.5M in 2025 from $12.2M in 2024, with net income falling to $2.1M ($0.46 per share) from $3.3M ($0.71 per share). The decline was driven by excess inventory at distributor Ashland Specialty Ingredients, decreased global demand particularly in China due to competition and tariffs, and reduced cosmetic ingredient sales. However, pharmaceutical sales increased 15% and medical lubricants rose 4%, with the company receiving pharmacy benefit manager approvals for Renacidin and entering new distribution agreements.
United-Guardian reported a 16.3% revenue decline in Q2 2025, primarily due to weak cosmetic ingredient sales from distributor inventory issues. Medical lubricants and pharmaceutical products showed growth, with management hopeful for cosmetic sales recovery in the second half of the year.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Jul 28, 2026
$0.30
Aug 4, 2026
recurring
Feb 9, 2026
$0.25
Feb 17, 2026
recurring
Jul 25, 2025
$0.25
Aug 1, 2025
recurring
Feb 10, 2025
$0.35
Feb 18, 2025
recurring
Jul 23, 2024
$0.35
Jul 31, 2024
recurring
Stock splits
Historical share-structure events and their execution dates.